NCT06329895View on ClinicalTrials.gov

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

June 10, 2024

Study Completion Date

June 10, 2024

Conditions
Advanced Non-small Cell Lung CancerEGFR MutationHER2 MutationHealthy Volunteers
Interventions
DRUG

BAY2927088

Oral administration.

DRUG

Dabigatran etexilate

Oral administration.

DRUG

Rosuvastatin

Oral administration.

Trial Locations (1)

HA1 3UJ

PAREXEL International Early Phase Clinical Unit (London), Harrow

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06329895 - A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants | Biotech Hunter | Biotech Hunter